|1.||Schwartz, Michal: 4 articles (12/2004 - 06/2003)|
|2.||Kipnis, Jonathan: 3 articles (11/2007 - 06/2003)|
|3.||Ibarra, Antonio: 2 articles (01/2015 - 09/2007)|
|4.||Cruz, Yolanda: 2 articles (01/2015 - 09/2007)|
|5.||Jackson, William T: 2 articles (12/2014 - 01/2014)|
|6.||Xia, Xiao-Bo: 2 articles (05/2013 - 01/2011)|
|7.||Zhou, Xia: 2 articles (05/2013 - 01/2011)|
|8.||Zhang, Jingwu Z: 2 articles (07/2009 - 05/2005)|
|9.||Zheng, Biao: 2 articles (08/2008 - 05/2005)|
|10.||Gendelman, Howard E: 2 articles (11/2007 - 10/2007)|
04/01/2014 - "Effect of RSCs combined with COP-1 on optic nerve damage in glaucoma rat model."
10/25/2011 - "To explore the morphological and expressional changes of Th1 cells and Th2 cells in retina of a rat model of glaucoma vaccinated by Cop-1 (Copolymer-1) and elucidate the possible neuroprotection roles played by Th1/Th2. "
01/01/2011 - "Immediately following glaucoma induction, rats were immunized with COP-1. "
02/01/2010 - "Expression of NT-3 appeared earlier and stronger in the rats immunized with COP-1 than in rats with glaucoma. "
02/01/2010 - "Qualified rats were divided into 3 groups: glaucoma group, COP-1 immunization group, and PBS control group. "
12/27/2013 - "Increased PGI2 by Adv-COPI protects the kidney against I/R-induced oxidative stress, necrosis, apoptosis and autophagy."
12/27/2013 - "Adv-COPI significantly improved renal function by restoring renal blood flow, reducing nicotinamide adenine dinucleotide phosphate oxidase-derived and mitochondria-derived oxidative stress, and necrosis, apoptosis, and autophagy. "
|3.||Brain Injuries (Brain Injury)
01/01/1997 - "In phase III clinical trials Cop-1 was found to slow progression of disability and reduce the relapse rate in exacerbating-remitting multiple sclerosis (MS). "
03/01/1982 - "A preliminary open trial examined the ability of COP I to alter the course of disease in 12 patients with chronic progressive and 4 with exacerbating-remitting multiple sclerosis (MS). "
07/01/2009 - "Th17 and Th1 play an important role in multiple sclerosis for which copolymer I (COP-I) is a treatment option. "
05/03/2005 - "Copolymer-I (COP-I) has unique immune regulatory properties and is a treatment option for multiple sclerosis (MS). "
04/15/2003 - "Daily administration of Cop-1 is an approved treatment for multiple sclerosis. "
|5.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
07/01/2009 - "We described here that the treatment effect of COP-I correlated with its unique regulatory properties on differentiation and survival of Th17 in experimental autoimmune encephalomyelitis mice, which was mediated through down-regulation of STAT3 phosphorylation. "
01/01/1986 - "Copolymer I (Cop I) is being tested as a treatment for MS because it protects animals against experimental allergic encephalomyelitis, and because there is immunologic cross-reactivity reported between Cop I and myelin basic protein (MBP). "
07/01/2009 - "The study revealed the differential regulatory roles and the novel mechanism of action of COP-I chiefly responsible for its treatment efficacy in experimental autoimmune encephalomyelitis and multiple sclerosis."
01/01/1992 - "The successful use of the synthetic amino acid copolymer COP-1 as an immunomodulatory vaccine to suppress the onset of allergic encephalomyelitis in experimental animals has led to clinical trials with patients suffering from exacerbating remitting multiple sclerosis. "
08/01/2008 - "Copolymer-I (COP-I) is an unique immune regulatory polymer that has been shown to suppress experimental autoimmune encephalomyelitis (EAE) and is a treatment option for multiple sclerosis (MS). "
|4.||Proteins (Proteins, Gene)
|6.||Coat Protein Complex I (COPI)
|7.||Glutamic Acid (Glutamate)
|9.||Small Interfering RNA (siRNA)
|10.||Coatomer Protein (Archain)
|1.||Transplantation (Transplant Recipients)